Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database
Oslo University Hospital · Norwegian Cancer Society · +30 more institutions
Abstract
Background Most patients with path_MMR gene variants (Lynch syndrome (LS)) now survive both their first and subsequent cancers, resulting in a growing number of older patients with LS for whom limited information exists with respect to cancer risk and survival. Objective and design This observational, international, multicentre study aimed to determine prospectively observed incidences of cancers and survival in path_MMR carriers up to 75 years of age. Results 3119 patients were followed for a total of 24 475 years. Cumulative incidences at 75 years (risks) for colorectal cancer were 46%, 43% and 15% in path_ MLH1 , path_ MSH2 and path_ MSH6 carriers; for endometrial cancer 43%, 57% and 46%; for ovarian cancer…
Citation impact
- FWCI
- 34.33
- Percentile
- 100%
- References
- 20
Authors
39- PMPål MøllerCorresponding
Oslo University Hospital, Norwegian Cancer Society, Helios Universitätsklinikum Wuppertal
- TTToni T. Seppälä
University of Helsinki, Helsinki University Hospital
- IBInge Bernstein
Aalborg University Hospital, Copenhagen University Hospital
- EHElke Holinski‐Feder
LMU Klinikum, Medical Genetics Center
- PSPaulo Sala
Fondazione IRCCS Istituto Nazionale dei Tumori
Topics & keywords
- Lynch syndrome
- Cancer
- Lifetime risk
- Medicine
- Oncology
- Database
- Internal medicine
- DNA mismatch repair
- Good health and well-being
Funding
- SLSuomen Lääketieteen Säätiö
- HAHealth and Care Research Wales
- PGParc Geneteg Cymru
- CCancerfonden
- GDGeneralitat de Catalunya
- MDMinisterio de Economía y Competitividad
- JJJane ja Aatos Erkon Säätiö
- VVetenskapsrådet
- MRMedical Research Council
- NHNational Health and Medical Research Council
- IDInstituto de Salud Carlos III